KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Castle Biosciences (CSTL) Leases (2021 - 2026)

Castle Biosciences' Leases history spans 5 years, with the latest figure at $14.8 million for Q4 2025.

  • On a quarterly basis, Leases rose 27.72% to $14.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.8 million, a 27.72% increase, with the full-year FY2025 number at $14.8 million, up 27.72% from a year prior.
  • Leases hit $14.8 million in Q4 2025 for Castle Biosciences, down from $15.2 million in the prior quarter.
  • Over the last five years, Leases for CSTL hit a ceiling of $15.5 million in Q2 2025 and a floor of $232000.0 in Q4 2022.
  • Historically, Leases has averaged $10.9 million across 5 years, with a median of $11.6 million in 2023.
  • Biggest five-year swings in Leases: crashed 96.86% in 2022 and later soared 5204.31% in 2023.
  • Tracing CSTL's Leases over 5 years: stood at $7.4 million in 2021, then crashed by 96.86% to $232000.0 in 2022, then soared by 5204.31% to $12.3 million in 2023, then fell by 5.87% to $11.6 million in 2024, then grew by 27.72% to $14.8 million in 2025.
  • Business Quant data shows Leases for CSTL at $14.8 million in Q4 2025, $15.2 million in Q3 2025, and $15.5 million in Q2 2025.